CA224-047: A randomized, double-blind, phase II/III study of relatlimab (anti-LAG-3) in combination with nivolumab (anti-PD-1) versus nivolumab alone in previously untreated metastatic or unresectable melanoma

E. J. Lipson; G. V. Long; H. Tawbi; D. Schadendorf; V. G. Atkinson; M. Maurer; K. L. Simonsen; C. Harbison; F. S. Hodi

doi:10.1093/annonc/mdy289.058

CA224-047: A randomized, double-blind, phase II/III study of relatlimab (anti-LAG-3) in combination with nivolumab (anti-PD-1) versus nivolumab alone in previously untreated metastatic or unresectable melanoma

E. J. Lipson, G. V. Long, H. Tawbi, D. Schadendorf, V. G. Atkinson, M. Maurer, K. L. Simonsen, C. Harbison, F. S. Hodi

Research output: Contribution to journal › Article › peer-review

Original language	English (US)
Pages (from-to)	viii464-viii465
Journal	Annals of oncology : official journal of the European Society for Medical Oncology
Volume	29
DOIs	https://doi.org/10.1093/annonc/mdy289.058
State	Published - Oct 1 2018

ASJC Scopus subject areas

Hematology
Oncology

Access to Document

10.1093/annonc/mdy289.058

Cite this

Lipson, E. J., Long, G. V., Tawbi, H., Schadendorf, D., Atkinson, V. G., Maurer, M., Simonsen, K. L., Harbison, C., & Hodi, F. S. (2018). CA224-047: A randomized, double-blind, phase II/III study of relatlimab (anti-LAG-3) in combination with nivolumab (anti-PD-1) versus nivolumab alone in previously untreated metastatic or unresectable melanoma. Annals of oncology : official journal of the European Society for Medical Oncology, 29, viii464-viii465. https://doi.org/10.1093/annonc/mdy289.058

CA224-047: A randomized, double-blind, phase II/III study of relatlimab (anti-LAG-3) in combination with nivolumab (anti-PD-1) versus nivolumab alone in previously untreated metastatic or unresectable melanoma. / Lipson, E. J.; Long, G. V.; Tawbi, H. et al.
In: Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, 01.10.2018, p. viii464-viii465.

Research output: Contribution to journal › Article › peer-review

Lipson, EJ, Long, GV, Tawbi, H, Schadendorf, D, Atkinson, VG, Maurer, M, Simonsen, KL, Harbison, C & Hodi, FS 2018, 'CA224-047: A randomized, double-blind, phase II/III study of relatlimab (anti-LAG-3) in combination with nivolumab (anti-PD-1) versus nivolumab alone in previously untreated metastatic or unresectable melanoma', Annals of oncology : official journal of the European Society for Medical Oncology, vol. 29, pp. viii464-viii465. https://doi.org/10.1093/annonc/mdy289.058

Lipson EJ, Long GV, Tawbi H, Schadendorf D, Atkinson VG, Maurer M et al. CA224-047: A randomized, double-blind, phase II/III study of relatlimab (anti-LAG-3) in combination with nivolumab (anti-PD-1) versus nivolumab alone in previously untreated metastatic or unresectable melanoma. Annals of oncology : official journal of the European Society for Medical Oncology. 2018 Oct 1;29:viii464-viii465. doi: 10.1093/annonc/mdy289.058

Lipson, E. J. ; Long, G. V. ; Tawbi, H. et al. / CA224-047 : A randomized, double-blind, phase II/III study of relatlimab (anti-LAG-3) in combination with nivolumab (anti-PD-1) versus nivolumab alone in previously untreated metastatic or unresectable melanoma. In: Annals of oncology : official journal of the European Society for Medical Oncology. 2018 ; Vol. 29. pp. viii464-viii465.

@article{9e557ec003704081b074dc9c5ec2ed9d,

title = "CA224-047: A randomized, double-blind, phase II/III study of relatlimab (anti-LAG-3) in combination with nivolumab (anti-PD-1) versus nivolumab alone in previously untreated metastatic or unresectable melanoma",

author = "Lipson, {E. J.} and Long, {G. V.} and H. Tawbi and D. Schadendorf and Atkinson, {V. G.} and M. Maurer and Simonsen, {K. L.} and C. Harbison and Hodi, {F. S.}",

year = "2018",

month = oct,

day = "1",

doi = "10.1093/annonc/mdy289.058",

language = "English (US)",

volume = "29",

pages = "viii464--viii465",

journal = "Annals of oncology : official journal of the European Society for Medical Oncology",

issn = "0923-7534",

publisher = "Oxford University Press",

}

TY - JOUR

T1 - CA224-047

T2 - A randomized, double-blind, phase II/III study of relatlimab (anti-LAG-3) in combination with nivolumab (anti-PD-1) versus nivolumab alone in previously untreated metastatic or unresectable melanoma

AU - Lipson, E. J.

AU - Long, G. V.

AU - Tawbi, H.

AU - Schadendorf, D.

AU - Atkinson, V. G.

AU - Maurer, M.

AU - Simonsen, K. L.

AU - Harbison, C.

AU - Hodi, F. S.

PY - 2018/10/1

Y1 - 2018/10/1

UR - http://www.scopus.com/inward/record.url?scp=85074541583&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85074541583&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdy289.058

DO - 10.1093/annonc/mdy289.058

M3 - Article

C2 - 32137191

SN - 0923-7534

VL - 29

SP - viii464-viii465

JO - Annals of oncology : official journal of the European Society for Medical Oncology

JF - Annals of oncology : official journal of the European Society for Medical Oncology

ER -

CA224-047: A randomized, double-blind, phase II/III study of relatlimab (anti-LAG-3) in combination with nivolumab (anti-PD-1) versus nivolumab alone in previously untreated metastatic or unresectable melanoma

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this